Organon To Commercialize Samsung Bioepis’ Stelara Biosimilar In Canada
Samsung Bioepis and Organon have expanded their partnership with the addition of a sixth biosimilar, Pyzchiva (ustekinumab).
Generics Bulletin - June 22, 2026

‘Wake Up And Smell The Coffee’ – Industry Rails Against EU Biotech Act’s 12-Month SPC Extension
At Medicines for Europe’s legal affairs conference in Athens, delegates did not hold back in slamming the proposed 12-month extension to originator SPCs that is proposed in the EU Biotech Act.
Generics Bulletin - June 22, 2026

Pipeline Watch: Nine Approvals And Fourteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 22, 2026

Apogee Acquisition Ticks AbbVie’s I&I Boxes
US major is paying $10.9bn to get hold of zumilokibart.
Scrip - June 22, 2026

The Insight Room: Catching the Deadliest Cancer Earlier — Inside the PRECEDE–Azenta Partnership
In this episode of the Medtech Insight podcast, PRECEDE Foundation's Margaret Caspler and Azenta Life Sciences' Kathi Shea explore why early detection has lagged in pancreatic cancer, what it takes to run a biospecimen network at scale, and what a public-private partnership can do.
Medtech Insight - June 22, 2026

Sandoz Plans Capital Markets Day As It Opens New Biosimilars Facility
Sandoz has laid out plans for a capital markets day in September at the London Stock Exchange, announcing the event shortly after opening a new biosimilars development center in Slovenia.
Generics Bulletin - June 22, 2026

UK Leads The Way For Value-Based Procurement In Europe
New NHS guidance shifts medtech procurement from focusing on low cost to long-term value.
Medtech Insight - June 22, 2026

Sanofi Replaces R&D Chief Ashrafian With Xaira’s Paulo Fontoura
Sanofi's new CEO makes her first leadership move, swapping out her R&D chief for an AI-experienced physician-scientist as the company hunts for its next blockbuster.
Scrip - June 22, 2026

Haleon’s Supply Chain Chief On Building For Growth In India And Beyond
Haleon is making its play in India, where it hopes a £175m plant and a 20-rupee Sensodyne pack will help turn a vast untreated market into sustainable, long-term growth, chief supply chain officer Namrata Patel tells HBW Insight.
HBW Insight - June 22, 2026

Early-Stage Medtech Funding Is Contracting – And The Pipeline Will Feel It
Early-stage medtech funding is contracting sharply, while capital has piled into later-stage, de-risked assets. Three investors at the front lines of that gap explain what it takes to survive it, and what happens to the pipeline if fewer companies do.
Medtech Insight - June 22, 2026

MDSAP Move Underlines MHRA’s Global Device Regulatory Ambitions
Industry has welcomed the UK MHRA’s stated intention to move up to full membership of the Medical Device Single Audit Program.
Medtech Insight - June 22, 2026

How Computational Tools Are Opening Drug Discovery To Outsiders
A high school student’s nanobody design, presented to a packed room at the American Academy of Neurology, is a striking signal that the barriers to computational drug design are collapsing far faster than the industry’s instincts and institutions are adjusting.
In Vivo - June 22, 2026

Biotech’s Second Half: Resilience Under Pressure, Dealmaking On New Terms
Deal value is up and capital markets are functioning, but preclinical valuations have collapsed, China commands 30% of the global pipeline and AI is reshaping R&D faster than most companies can respond.
In Vivo - June 22, 2026

US FDA Warns Revlon, Fragrance Creators Holds Fly-In; News Roundup
Revlon Group Holdings did not properly test talc components in a drug product for asbestos, according to the US Food and Drug Administration.
HBW Insight - June 22, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Pfizer lays out oncology direction; key topics at BIO 2026; GLP-1 access causes problems for obesity studies; GLP-1 use insights from Brazil; and Q1’s top 10 drugs.
Scrip - June 22, 2026

US FDA’s Stelo Pediatric Clearance Marks First OTC CGM For Children, Backed By Real-World Data
The FDA has cleared Dexcom's Stelo continuous glucose monitor for OTC use by children ages 2 and up who do not use insulin, making it the first nonprescription CGM cleared for pediatric use. The authorization was supported in part by real-world evidence.
HBW Insight - June 22, 2026